WuXi Biologics (Cayman) Inc. (2269.HK) HKSE

Currency In HKD

AD

Valuation

Market Cap117.92B
Enterprise Value111.8B
P/E Ratio33.21
PEG Ratio1.68
Price/Sales Ratio7.05
Price/Book Ratio3.43
Enterprise/Revenue6.79
Enterprise/EBITDA18.13

Fiscal Year

Fiscal YearDecember 31, 2025
Most Recent QuarterJune 30, 2026

Profitability

Profit Margin0.21
Operating Margin0.32
AD

Management Effectiveness

Return On Assets0.08
Return On Equity0.11

Income Statement

Revenue21.79B
Revenue/Share5.77
Gross Profit10.02B
EBITDA7.92B
Net Income4.91B
Diluted EPS1.16

Balance Sheet

Total Cash13.04B
Total Cash/Share3.18
Total Debt2.73B
Total Debt/Equity0.06
Current Ratio3.04
Book Value Per Share13.32

Price History

52-Week Change30.56
52-Week High54.45
52-Week Low28.48
Moving Average 50 Days43.5
Moving Average 200 Days37.02

Statistics

Average Volume36.11M
Shares Outstanding4.14B
% Held by Institutions0.23

Dividend And Splits

Trailing Annual Dividend Rate0
Trailing Annual Dividend Yield0
Payout Ratio0
Last Split Factor3:1
Last Split DateNovember 16, 2020
AD